MannKind Corporation will release Q3 2025 financial results on November 5, 2025, followed by a webcast discussion.
Quiver AI Summary
MannKind Corporation announced that it will release its third quarter 2025 financial results on November 5, 2025, before the market opens. The company will host a webcast at 9 a.m. Eastern Time to discuss these results and provide a business update, which can be accessed through a link on MannKind's website. A replay of the webcast will be available within 24 hours and will remain accessible for approximately 90 days. MannKind focuses on developing innovative treatments for cardiometabolic and orphan lung diseases, aiming to address serious unmet medical needs and integrate its therapies into patients' daily lives.
Potential Positives
- MannKind Corporation will provide an opportunity for investors and analysts to engage with the company during a webcast that discusses the upcoming financial results and business update, enhancing transparency and communication.
- The scheduled release of third quarter financial results signals the company's ongoing commitment to keep stakeholders informed about its performance and strategic direction.
- MannKind's focus on innovative, patient-centric solutions in chronic disease care positions the company favorably within the biopharmaceutical industry, highlighting its commitment to addressing unmet medical needs.
Potential Negatives
- Delayed financial results release could raise concerns among investors about the company's performance and transparency.
- Failure to achieve expected milestones or targets in the quarter may lead to decreased investor confidence.
- The emphasis on addressing "serious unmet medical needs" may highlight ongoing challenges or deficiencies in the company's current product portfolio.
FAQ
When will MannKind Corporation release its Q3 2025 financial results?
MannKind Corporation will release its third quarter 2025 financial results before the market opens on November 5, 2025.
How can I access the MannKind Q3 2025 financial results webcast?
The webcast discussing MannKind's Q3 2025 financial results can be accessed via their website at https://investors.mannkindcorp.com/events-and-presentations.
What time is the MannKind Q3 2025 webcast scheduled to start?
The MannKind Q3 2025 webcast is scheduled to begin at 9 a.m. Eastern Time.
Will there be a replay of the MannKind Q3 2025 financial results webcast?
Yes, a replay of the webcast will be available within 24 hours and accessible for approximately 90 days.
What focus areas does MannKind Corporation specialize in?
MannKind Corporation specializes in cardiometabolic and orphan lung diseases, including treatments for diabetes and pulmonary hypertension.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MNKD Insider Trading Activity
$MNKD insiders have traded $MNKD stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $MNKD stock by insiders over the last 6 months:
- STEVEN B. BINDER has made 0 purchases and 4 sales selling 231,674 shares for an estimated $982,304.
- STUART A TROSS (Chief People & Workpl Officer) sold 47,000 shares for an estimated $250,980
- DAVID THOMSON (EVP Genl Counsel & Secretary) has made 0 purchases and 3 sales selling 41,990 shares for an estimated $190,355.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MNKD Hedge Fund Activity
We have seen 97 institutional investors add shares of $MNKD stock to their portfolio, and 122 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 4,613,019 shares (+18.8%) to their portfolio in Q2 2025, for an estimated $17,252,691
- UBS GROUP AG removed 4,454,349 shares (-67.9%) from their portfolio in Q2 2025, for an estimated $16,659,265
- AVORO CAPITAL ADVISORS LLC removed 2,900,000 shares (-33.1%) from their portfolio in Q2 2025, for an estimated $10,846,000
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 1,617,202 shares (-59.5%) from their portfolio in Q2 2025, for an estimated $6,048,335
- MILLENNIUM MANAGEMENT LLC removed 1,341,064 shares (-23.0%) from their portfolio in Q2 2025, for an estimated $5,015,579
- D. E. SHAW & CO., INC. removed 1,314,956 shares (-34.3%) from their portfolio in Q2 2025, for an estimated $4,917,935
- STATE STREET CORP added 1,275,939 shares (+13.5%) to their portfolio in Q2 2025, for an estimated $4,772,011
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MNKD Analyst Ratings
Wall Street analysts have issued reports on $MNKD in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/13/2025
- RBC Capital issued a "Outperform" rating on 08/26/2025
To track analyst ratings and price targets for $MNKD, check out Quiver Quantitative's $MNKD forecast page.
$MNKD Price Targets
Multiple analysts have issued price targets for $MNKD recently. We have seen 4 analysts offer price targets for $MNKD in the last 6 months, with a median target of $10.5.
Here are some recent targets:
- Brandon Folkes from HC Wainwright & Co. set a target price of $11.0 on 10/13/2025
- Andreas Argyrides from Oppenheimer set a target price of $15.0 on 09/05/2025
- Tiago Fauth from Wells Fargo set a target price of $10.0 on 09/03/2025
- Douglas Miehm from RBC Capital set a target price of $8.0 on 08/26/2025
Full Release
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 2025.
MannKind will host a webcast beginning at 9 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations . A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at
mannkindcorp.com
.
